ストックスクリーナーアプリを入手
20.98
1.00%
-0.165
前日終値:
$21.15
開ける：
$21.21
24時間の取引高:
81,475
Relative Volume:
0.09
時価総額：
$2.55B
収益：
$434.48M
当期純損益:
$68.15M
株価収益率:
20.78
EPS:
1.01
ネットキャッシュフロー:
$114.96M
1週間 パフォーマンス:
-3.46%
1か月 パフォーマンス:
-0.38%
6か月 パフォーマンス:
+26.68%
1年 パフォーマンス:
+52.40%
1日の値動き範囲:
$20.87
$21.21
1週間の範囲:
$20.44
$21.63
52週間の値動き範囲:
$13.00
$24.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
名前
Catalyst Pharmaceuticals Inc
セクター
電話
(305) 529-2522
住所
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CPRX | 20.98 | 2.55B | 434.48M | 68.15M | 114.96M | 1.01 |
| VRTX | 448.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.33 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.40 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.38 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.62 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-14 | 開始されました | Citigroup | Buy |
| 2024-03-07 | 開始されました | BofA Securities | Buy |
| 2023-12-21 | 開始されました | Oppenheimer | Outperform |
| 2022-08-24 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 再開されました | Piper Jaffray | Overweight |
| 2016-10-05 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2013-10-21 | 繰り返されました | Aegis Capital | Buy |
| 2013-09-24 | 開始されました | Maxim Group | Buy |
| 2013-09-06 | 繰り返されました | Aegis Capital | Buy |
| 2013-04-18 | 開始されました | Aegis Capital | Buy |
| 2012-08-27 | アップグレード | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | アップグレード | Merriman | Sell → Neutral |
| 2009-05-29 | ダウングレード | Hapoalim | Neutral → Underperform |
| 2009-05-29 | ダウングレード | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 開始されました | Merriman Curhan Ford | Buy |
| 2007-11-28 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 開始されました | Stifel Nicolaus | Buy |
| 2007-01-05 | 開始されました | First Albany | Buy |
すべてを表示
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan
GSA Capital Partners LLP Makes New $625,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat
Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Stephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight Recommendation - MSN
Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga
Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat
CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals' (CPRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Q3 2024 Earnings - TipRanks
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance - Investing.com
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 - Marketscreener.com
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance By Investing.com - Investing.com Canada
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings - Simply Wall St
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides - The Bakersfield Californian
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Prev - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Catalyst Pharmaceuticals Q3 2024 Earnings Preview - MSN
Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
A Peek at Catalyst Pharmaceuticals's Future Earnings - Benzinga
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
DekaBank Deutsche Girozentrale Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc (CPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):